A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation-Reference-Cited by-同舟云学术

A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

Published:2018-10-30 Issue:12 Volume:10 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Castroviejo‐Bermejo Marta¹,Cruz Cristina¹²³,Llop‐Guevara Alba¹,Gutiérrez‐Enríquez Sara⁴,Ducy Mandy⁵⁶⁷,Ibrahim Yasir Hussein¹,Gris‐Oliver Albert¹,Pellegrino Benedetta¹⁸,Bruna Alejandra⁹,Guzmán Marta¹,Rodríguez Olga¹,Grueso Judit¹,Bonache Sandra⁴,Moles‐Fernández Alejandro⁴,Villacampa Guillermo¹⁰,Viaplana Cristina¹⁰,Gómez Patricia³¹¹,Vidal Maria³¹¹,Peg Vicente¹²¹³,Serres‐Créixams Xavier¹⁴,Dellaire Graham¹⁵,Simard Jacques⁷,Nuciforo Paolo¹³¹⁶,Rubio Isabel T¹³¹⁷,Dienstmann Rodrigo¹⁰,Barrett J Carl¹⁸,Caldas Carlos⁹¹⁹,Baselga José²⁰²¹,Saura Cristina³¹¹,Cortés Javier¹³²²²³,Déas Olivier²⁴,Jonkers Jos²⁵^ORCID,Masson Jean‐Yves⁵⁶,Cairo Stefano²⁴,Judde Jean‐Gabriel²⁴,O'Connor Mark J²⁶,Díez Orland⁴²⁷,Balmaña Judith²³^ORCID,Serra Violeta¹¹³^ORCID

Affiliation:

1. Experimental Therapeutics Group Vall d'Hebron Institute of Oncology Barcelona Spain

2. High Risk and Familial Cancer Group Vall d'Hebron Institute of Oncology Barcelona Spain

3. Department of Medical Oncology Hospital Vall d'Hebron Universitat Autònoma de Barcelona Barcelona Spain

4. Oncogenetics Group Vall d'Hebron Institute of Oncology Barcelona Spain

5. Genome Stability Laboratory CHU de Québec Research Center Québec City QC Canada

6. Department of Molecular Biology, Medical Biochemistry and Pathology Laval University Cancer Research Center Québec City QC Canada

7. CHU de Quebec ‐ Université Laval Research Center Genomics Center CHUL Québec City QC Canada

8. Department of Medical Oncology University Hospital of Parma Parma Italy

9. Cancer Research UK Cambridge Institute and Department of Oncology Li Ka Shing Centre University of Cambridge Cambridge UK

10. Oncology Data Science (OdysSey Group) Vall d'Hebron Institute of Oncology Barcelona Spain

11. Breast Cancer and Melanoma Group Vall d'Hebron Institute of Oncology Barcelona Spain

12. Pathology Department Vall d'Hebron University Hospital Barcelona Spain

13. CIBERONC Instituto de Salud Carlos III Madrid Spain

14. Department of Radiology Hospital Vall d'Hebron Universitat Autònoma de Barcelona Barcelona Spain

15. Department of Pathology Dalhousie University Halifax NS Canada

16. Molecular Oncology Group Vall d'Hebron Institute of Oncology Barcelona Spain

17. Breast Surgical Unit Breast Cancer Center Hospital Vall d'Hebron Universitat Autònoma de Barcelona Barcelona Spain

18. AstraZeneca Waltham MA USA

19. Breast Cancer Programme Cancer Research UK (CRUK) Cambridge Cancer Centre Cambridge UK

20. Human Oncology and Pathogenesis Program (HOPP) Memorial Sloan Kettering Cancer Center New York NY USA

21. Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA

22. Department of Oncology Ramón y Cajal University Hospital Madrid Spain

23. Vall d'Hebron Institute of Oncology Barcelona Spain

24. XenTech Evry France

25. Division of Molecular Pathology and Cancer Genomics The Netherlands Cancer Institute Amsterdam The Netherlands

26. Oncology Innovative Medicines and Early Clinical Development Biotech Unit AstraZeneca Cambridge UK

27. Clinical and Molecular Genetics Area Hospital Vall d'Hebron Universitat Autònoma de Barcelona Barcelona Spain

Funder

Instituto de Salud Carlos III

Fundación Científica Asociación Española Contra el Cáncer

Agència de Gestió d’Ajuts Universitaris i de Recerca

Canadian HIV Trials Network, Canadian Institutes of Health Research

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201809172

Reference71 articles.

1. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

2. Disambiguate: An open-source application for disambiguating two species in next generation sequencing data from grafted samples

3. Breast-Cancer Risk in Families with Mutations in PALB2

4. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

5. Geminin deploys multiple mechanisms to regulate Cdt1 before cell division thus ensuring the proper execution of DNA replication

Cited by 194 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors;British Journal of Cancer;2024-09-13

2. Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial;2024-08-30

3. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models;Genome Medicine;2024-08-26

4. Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches;Frontiers in Oncology;2024-08-16

5. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29